Clinical trials of multiple sclerosis

Interferon Therapy of Multiple Sclerosis

Volumn , Issue , 1997, Pages 449-508

  Hobart, Jeremy C ^a   Thompson, Alan J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84889540233     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (50)

1. Poser CM, Paty DW, McDonald WI, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-231.
2. Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991; 29:53-62.
3. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996; 46:907-910.
4. Noseworthy JH. Immunosuppressive therapy in multiple sclerosis: pros and cons. Int MS J 1994; 1:79-89.
5. Polman CH, Dahlke K, Thompson AJ, et al. Interferon beta-lb in secondary progressive multiple sclerosis-outline of the clinical trial. Mult Scler 1995; 1:S51-S54.
6. Whitaker JN, McFarland HF, Rudge P, Reingold SC. Outcomes assessment in multiple sclerosis trials: a critical analysis. Mult Scler 1995; 1:37-47.
7. Rudick R, Antel J, Confavreux C, et al. Clinical outcomes assessment in multiple sclerosis. Ann Neurol (in press).
8. Gothan A, Brown R, Marsden C. Depression in Parkinson’s disease: a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry 1986; 49: 381-389.
9. Brown R, MacCarthy B, Jahanshahi M, Marsden C. Accuracy of self-reported disability in patients with parkinsonism. Arch Neurol 1989; 46: 955-959.
10. The IFNB Multiple Sclerosis Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multi-center, randomised, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-661.
11. Devinsky O. Outcomes research in neurology: incorporating health-related quality of life. Ann Neurol 1995; 37(2):141-142.
12. Gill TM. Quality of life assessment. J Roy Soc Med 1995; 88:680-682.
13. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis cohort with 25 years follow up. Brain 1993; 116:117-134.
14. Streiner DL, Norman GR. Health Measurement Scales: A Practical Guide to Their Development and Use, 2nd ed. Oxford: Oxford University Press, 1995.
15. Weinshenker BG. Natural history of multiple sclerosis. Ann Neurol 1994; 36:S6-S11.
16. Hobart JC, Lamping DL, Thompson AJ. Evaluating neurological outcome measures: the bare essentials. J Neurol Neurosurg Psychiatry 1996; 60: 127-130.
17. Guyatt G, Freeny D, Patrick D. Measuring health-related quality of life. Ann Intern Med 1993; 118:622-629.
18. Patrick D, Deyo R. Generic and disease specific measures in assessing health status and quality of life. Med Care 1989; 27(Suppl):217-232.
19. Morrisey SP, Miller DH, Kendall BE, et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. Brain 1993; 116:135-146.
20. Losseff NA, Kingsley DPE, Miller DH, McDonald WI, Thompson AJ. Clinical and magnetic resonance imaging in primary and secondary progressive multiple sclerosis. Mult Scler 1996; 1:218-222.
21. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33:1444-1452.
22. McDonald WI, Miller DH, Thompson AJ. Are magnetic resonance findings predictive of clinical outcome in therapeutic trials in multiple sclerosis? The dilemma of interferon-β. Ann Neurol 1994; 36(1):14-18.
23. Fillipi M, Horsfield MA, Tofts PS, Barkof F, Thompson AJ, Miller DH. Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis. Brain 1995; 118:1601-1612.
24. Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 1996; 39:6-16.
25. Willoughby EW, Paty DW. Scales for rating impairment in multiple sclerosis: a critique. Neurology 1988; 38:1793-1798.
26. Noseworthy JH. Clinical scoring methods for multiple sclerosis. Ann Neurol 1994; 36:S80-S85.
27. Noseworthy JH, Vander voort MK, Wong CJ, Ebers GC. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. Neurology 1990; 40:971-975.
28. Goodkin DE, Cookfair D, Wende K, et al. Inter- and intra-rater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Neurology 1992; 42:859-863.
29. Francis DA, Bain P, Swan AV, Hughes RAC. An assessment of disability rating scales used in multiple sclerosis. Arch Neurol 1991; 48:299-301.
30. McDowell I, Newell C. Measuring Health: A Guide to Rating Scales and Questionnaires. Oxford: Oxford University Press, 1987.
31. Wilkin D, Hallam L, Doggett M-A. Measures of Need and Outcome for Primary Health Care. Oxford: Oxford University Press, 1994.
32. Bowling A. Measuring Disease: A Review of Disease Specific Quality of Life Measurement Scales. Buckingham, Philadelphia: Open University Press, 1995.
33. Sharrack B, Hughes RAC. Clinical scales for multiple sclerosis. J Neurol Sci 1996; 135:1-9.
34. American Education Research Association, American Psychological Association and National Council on Measurement in Education. Standards for Education and Psychological Testing. Washington, DC: American Psychological Association, 1985.
35. Medical Outcomes Trust. Instrument review criteria. Med Outcomes Trust Bull 1995; 3(4):i-iv.
36. Fitzpatrick R. Applications of health status measures. In: Jenkinsin C, ed. Measuring Health and Medical Outcomes. London: UCL Press, 1994.
37. Ware JE, Sherbourne DC. The MOS 36-item short form health survey (SF- 36). I. Conceptual framework and item selection. Med Care 1992; 30(6): 473-483.
38. McHorney CA, Ware JE, Raczek AE. The MOS 36-item Short-Form Health Survey (SF-36). II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31(3):247-263.
39. Freeman JA, Langdon DW, Thompson AJ. The health-related quality of life of people with advanced multiple sclerosis. Arch Phys Med Rehabil (in press).
40. Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW. A health-related quality of life measure for multiple sclerosis. Qual Life Res 1995; 4:187-206.
41. Eddy DM. Should we change the rules for evaluating medical technologies? In: Gelijns AC, ed. Modern Methods of Clinical Investigation. Washington, DC: National Academic Press, 1990
42. Brown JR, et al. The design of clinical studies to assess therapeutic efficacy in multiple sclerosis. Neurology 1979; 21:2-23.
43. Herndon RM, Murray TJ. Proceedings of the international conference on therapeutic trials in multiple sclerosis. Arch Neurol 1983; 40:663-710.
44. Black N. Why we need observational studies to evaluate the effectiveness of health care. Br Med J 1996; 312(7040):1215-1218.
45. Nauta JJP, Thompson AJ, Barkhof F, Miller DH. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: statistical power of parallel-groups and crossover designs. J Neurol Sci 1994; 122:6-14.
46. Weinshenker B, Issa M, Baskerville J. Meta-analysis of the placebo treated groups in clinical trials of progressive MS. Neurology (in press).
47. Polman CH, Hartung HP. The treatment of multiple sclerosis: current and future. Curr Opin Neurol 1995; 8:200-209.
48. Ellison GW, Myers LW, Leake BD, et al. Design strategies for multiple sclerosis clinical trials. Ann Neurol 1994; 36:S108-S112.
49. Thompson AJ, Noseworthy JH. New treatment for multiple sclerosis: a clinical perspective. Curr Opin Neurol 1996; 9:187-198.
50. Foa R. Ethical considerations raised by clinical trials. In: Goodkin DE, Rudick RA, eds. Multiple Sclerosis: Advances in Clinical Trial Design, Treatment and Future Perspectives. London: Springer-Verlag, 1996.